

31. The antibody of Claim 29, which inhibits *in vitro* production of IL-2 by T-lymphocytes.

32. The antibody of Claim 31, wherein said antibody inhibits IL-2 production when added to a T-lymphocyte containing culture at a concentration of at least 10 μ g/ml.

33. The monoclonal antibody of Claim 29, which is a primatized antibody.

34. The monoclonal antibody of Claim 29, which is a human, chimeric mal/human or humanized antibody.

35. The primatized monoclonal antibody of Claim 33, which contains a human immunoglobulin gamma-1 or gamma-4 constant region.

36. The primatized antibody of Claim 35, wherein said gamma-4 constant region has been mutagenized to eliminate residual FCR binding and/or has been mutagenized in the hinge region to enhance the stability of the heavy chain disulfide bond interaction.

37. A composition containing a monoclonal antibody according to Claim 29, and a pharmaceutically acceptable carrier.--